Drug Nearly Doubles Survival in Advanced Pancreatic Cancer—Daraxonrasib Overcomes 'Undruggable' Disease

A groundbreaking new drug called daraxonrasib has demonstrated the ability to nearly double survival rates in patients with advanced metastatic pancreatic cancer, historically one of the most lethal malignancies. Previously, approximately 97% of patients diagnosed with metastatic pancreatic cancer between 2015 and 2021 died within five years. This innovative treatment targets mutations previously considered 'undruggable,' representing a significant paradigm shift in pancreatic cancer therapy. The advancement offers hope to patients facing this aggressive disease and underscores the importance of precision medicine in oncology.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: June 7, 2026 at 10:11 AM



